BridgeBio (BBIO) shares after now down 2%, or $1.23, to $73.27 in morning trading. Pfizer (PFE) said its tafamidis settlements with generic drug manufacturers extend the effective U.S. patent expiry date to June 1, 2031, subject to the outcome of other litigation. Pfizer had previously anticipated a significant decline in U.S. revenues for tafamidis beginning in 2029 upon patent expiry. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031, the company said.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement
- Pfizer announces three settlement agreements for Vyndamax
- BridgeBio could trade to $90-$110 on Pfizer settlement, says Mizuho
- Apparent Hikma settlement ‘key positive’ for BridgeBio, says Barclays
- 3 Best Stocks to Buy This Week, According to Analysts – April 26-May 1